HANSOH PHARMA(HK:03692) 智通财经网·2025-10-17 01:32Core Viewpoint - Hansoh Pharmaceutical (03692) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd, granting Roche exclusive global rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The licensing agreement was established between Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. (collectively referred to as "licensors") and Roche (the "licensee") [1] - The licensors will receive an upfront payment of $80 million and are eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Additionally, the licensors will receive tiered royalties on future potential product sales [1] Group 2: Company Background - Roche is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange and was founded in 1896 in Basel, Switzerland [1] - Roche has evolved into a leading global biotechnology company and a leader in in vitro diagnostics [1] - The board of Hansoh Pharmaceutical believes that entering into this licensing agreement is in the best interests of the company and its shareholders [1]